Weiss 1995.

Methods	Design: RCT Study dates: April to July 1993 Malaria transmission pattern and local antimalarial drug resistance: "Incidence of new cases of falciparum malaria during the rainy seasons has been measured at 90% in adults. P. falciparum accounts for > 95% of all malaria in Saradidi" Adverse event monitoring: "Each subject was visited daily at home by an assigned field worker, who asked about symptoms of malaria or drug side effects, obtained malaria smears, or administered drug doses if the subject was not at school"
Participants	Number enrolled: 169 Inclusion criteria: aged 9 to 14 years. "Screening consisted of a physical examination, a urine pregnancy test for girls, and blood tests for complete blood cell count; blood urea nitrogen, serum alanine aminotransferase, and glucose‐6 phosphate dehydrogenase (G6PD) levels; and hemoglobin electrophoresis" Exclusion criteria: none mentioned Country of recruitment: Saradidi Rural Health Project, Nyanza province, Kenya on the shores of Lake Victoria Country of malaria exposure: Saradidi Rural Health Project, Nyanza province, Kenya on the shores of Lake Victoria Duration of exposure to malaria: study duration 4 months Type of participants: Kenyan residents, semi‐immune
Interventions	1. Melfoquine (1 x 125 mg tablet) weekly, with a second dose given on the third day of the study, equal to their usual weekly medication. 2. Doxycycline (1 x 50 mg tablet) daily 3. Primaquine 4. Multivitamin (1 x tablet containing vitamin A, 2500 IU, thiamine, 1 mg, riboflavin, 0.5 mg, nicotinamide, 7.5 mg, ascorbic acid, 15 mg, vitamin 0 3, 250 IU) daily Co‐interventions: After baseline malaria smears, all subjects received curative therapy for preexisting malaria: 7 days of quinine bisulfate, 300 mg three times daily, and doxycycline, 50 mg twice daily. The first dose of prophylactic drug was given starting the day after curative therapy finished
Outcomes	Included in the review: 1. Clinical cases of malaria 2. Episodes of parasitaemia 3. Discontinuations of study drug due to adverse effects Outcomes assessed not included in the review: 4. Laboratory tests; complete blood cell counts, blood urea nitrogen and serum alanine aminotransferase 5. Mean number of symptoms reported per subject: nausea, abdominal pain, diarrhoea, headache, fever
Notes	Funding sources: Financial support: USA Naval Medical Research and Development Command (work unit no. 623002A.81 0.00 J0 I.HFX. J433). Kenya Medical Research Institute. USA Army Medical Research and Materiel Command Provisional (contract no. DAMDI7‐92‐V‐20J2)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Students from each village school were separately randomized, to control for geographic variation in malaria transmission" Comment: no description of how randomization was performed
Allocation concealment (selection bias)	Unclear risk	"All medications were in brown envelopes and were administered 7 days each week by I field worker at each school" Comment: no mention of whether envelopes were sealed or if field workers had access to their content
Blinding of participants and personnel (performance bias) Adverse effects/events	Unclear risk	Comment: no mention of whether participants were blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"None of the malaria slide readers knew which drugs the subjects were taking. None of the field workers visiting the homes daily to ask about symptoms or clinical staff evaluating and treating subjects at the Saradidi Clinic knew which drugs the subjects were taking. If there was concern about a drug side effect, the clinical staff would consult the medical monitor, who would break the code for that subject. This occurred only four times during the studies"
Incomplete outcome data (attrition bias); efficacy	Unclear risk	N/A
Incomplete outcome data (attrition bias); safety	Unclear risk	Comment: number included in the safety analysis not reported
Selective reporting (reporting bias); efficacy	Unclear risk	N/A
Selective reporting (reporting bias); safety	Unclear risk	Comment: mean number of symptoms reported per subject during 11 weeks of the study were reported. A targeted list of symptoms was reported, with everything else included in ‘all other’. It was unclear what this list included
Other bias	Low risk	Financial support: USA Naval Medical Research and Development Command (work unit no. 623002A.81 0.00 J0 I.HFX. J433). Kenya Medical Research Institute. USA Army Medical Research and Materiel Command Provisional (contract no. DAMDI7‐92‐V‐20J2)